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Abstract
We describe a case of fungal keratitis due to Beauveria bassiana in a
farmer with Fuchs’ dystrophy, treated with amphotericin B.
Surgery with penetrating keratoplasty was necessary to resolve
the lesions. Susceptibility testing and molecular sequencing
permitted the identification and treatment of this rare aetiological
agent of invasive fungal disease.
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Case Report
In early December 2012, a 76-year-old woman affected by
chronic obstructive pulmonary disease, chronic atrial
fibrillation, arterial hypertension, rheumatoid arthritis,
hypothyroidism, osteoporosis and Fuchs’ dystrophy presented
to the hospital for corneal oedema with a white infiltrated
ulcer in the right eye (Fig. 1), without previous history of
trauma.
The woman lived in a rural area near Mantova, in northern
Italy. She bred cattle, but she denied any contact with pesticides.
The patient had already received a corneal endothelial
transplant in the left eye in June 2012 for Fuchs’ dystrophy,
while a perforating keratoplasty was already planned in the
right eye for a previous central leucoma and Fuchs’ dystrophy
in January 2013. The patient’s right eye was receiving local
chronic therapy with dexamethasone 0.2% eye drops three
times a day and ganciclovir gel three times a day.
The patient had already been hospitalized twice for bacterial
infection in the right eye (July and December 2011) with
positive culture for Serratia marcescens; she also suffered with
recurrent herpes simplex keratitis in this eye.
Her visual acuity was 1.30 LogMAR (logarithm of the minimum
angle of resolution) on the right and 0.07 LogMAR on the left.
Two corneal scrapings were collected for conventional
microscopic and cultural diagnostic procedures. Microscopic
examination of corneal scrapings with calcofluor white fluo-
rescent staining did not show the presence of fungal elements.
The culture media used were blood agar, MacConkey’s agar,
chocolate agar and Sabouraud’s dextrose agar (SDA). Corneal
scrapings were plated into SDA (Oxoid, Basingstoke, UK) and
incubated at 25, 30 and 37°C. One week later, her visual acuity
was stable and the stromal keratitis was unchanged; the
cultures were positive for Staphylococcus epidermidis and for a
mould compatible with Beauveria spp. [1]. Colonies were fast
growing, reaching diameters of 4.5 cm in 13 days at 30°C on
potato dextrose agar (Difco Laboratories, Detroit, MI, USA).
They were densely cottony to flocculent, with droplets of
exudate on the surface, yellowish white, raised and dome
shaped. For identification of fungal species grown in SDA,
fragments of culture were placed onto glass slides for staining
with lactophenol cotton blue. Conidiogenous cells occurred in
sporodochial clusters and were slightly swollen at the base and
narrowed at the tip to form a zigzag rachis. Conidia were oval
to subglobose and apiculate, and measured 2 to 3 lm long and
1.5 to 2 lm wide (Fig. 2). The difficulties in identifying isolates
of Beauveria based solely on morphological characteristics have
led researchers to consider the use of molecular tools. Total
genomic DNA was extracted from mycelia of the fungus grown
on potato dextrose agar medium using the silica beads method.
In brief, fungal mycelium was harvested from culture plates and
was added to 1.5 mL microcentrifuge tubes. Mycelium material
was suspended in 200 lL of a bead beating solution containing
TE buffer (Tris–HCl 10 mM (pH 8), EDTA 1 mM). Approx-
imately 100 mg of mixed diameter (425–600 lm) glass beads
(Sigma Aldrich, St Louis, MO, USA) for crushing of cell walls
were also added. The tubes were then placed into a Turbo Mix
TM adapter (Scientific Industries Inc., VWR International, Milan,
Italy) attachment for a Vortex Genie 2 (Fisher Bioblock
Scientific, Fischer Scientific SAS, Ilikirh Cedex, France) and
homogenized for 10 min at maximum speed. Then, the tubes
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were centrifuged for 10 min at 11 000 g. After centrifugation,
the supernatants were decanted to a sterile 1.5 mL microcen-
trifuge tube, and heated to 95°C for 10 min. The DNA obtained
by this procedure was suitable in less than an hour for PCR
amplification. Internal transcribed spacer (ITS) primers ITS1 and
ITS4 were used to amplify a ribosomal DNA (rDNA) ITS region
[2]. Primers NL1 and NL4 were used to amplify the D1–D2
region of the large-subunit (LSU) rDNA gene [3]. Both
PCR-amplified fragments were purified using the QIAquick
PCR purification kit, according to the manufacturer’s instruc-
tions (Qiagen, Hilden, Germany). The ITS and D1/D2 regions of
the 26S ribosomal DNAwas sequenced in both directions using
BIG DYE TERMINATOR v. 3.1 (Applied Biosystems, Foster City, CA,
USA) in an ABI Prism 3100 sequencer (Applied Biosystems).
Amplified ITS sequences were compared with the GenBank
Nucleotide Database (http://www.ncbi.nlm.nih.gov) using the
algorithm BLAST N [4]. The sequence of the nuclear ribosomal
ITS region from the case isolate was deposited in GenBank with
the accession number for ITS region HF675188 and for D1/D2
region HF675189.
The in vitro activities of amphotericin B, fluconazole,
itraconazole, voriconazole, posaconazole, anidulafungin, ca-
spofungin, micafungin and flucytosine were determined by a
broth microdilution method according to the standardized
procedure for antifungal susceptibility testing proposed by the
Clinical and Laboratory Standards Institute (CLSI) document
M38-A2 [5]. Readings were taken at 24 and 48 h. MIC results
were 2 mg/L for amphotericin B, >64 mg/L for fluconazole,
0.25 mg/L for itraconazole and voriconazole, and 0.06 mg/L
for posaconazole. The minimum effective concentrations of
echinocandins were 4 mg/L for anidulafungin and caspofungin,
and >8 mg/L for micafungin.
The patient was given a topical galenic therapy with
ceftazidime 0.9% eye drops six times a day, vancomycin 5%
eye drops six times a day and amphotericin B 0.15 % eye drops
six times a day [6–8].
Although the strain isolates showed susceptibility only for
voriconazole and posaconazole, we continued the therapy
with amphotericin B and vancomycin eye drops six times a day,
because neither voriconazole or posaconazole galenic eye
drops were available. Ceftazidime administration was discon-
tinued.
A week later the keratitis had improved, the stromal
infiltrate appeared to be smaller, and the anterior chamber
was always soft. After 30 days the corneal infiltrate was
clearer than before and the ulcer had resolved, so we
performed the planned perforating keratoplasty with phaco-
emulsification and implant of an intraocular artificial lens in the
right eye [9–11].
At the 20th day the keratoplasty was clear without signs of
infection. The patient presented best corrected visual acuity of
0.52 LogMar, intraocular pressure of 18 mmHg, and her
therapy was netilmicin 0.3% + dexamethasone 0.1% eye drops
six times a day, amphotericin B 0.15% eye drops six times a day
and acyclovir 400 mg orally three times a day.
(a) (b)
FIG. 2. Macroscopic and microscopic appearance of the isolates. (a) Rapid growing, white and densely woolly fungus with a white reverse. (b)
Microscopic examination of Beauveria bassiana show cell with globose bases and extended, denticulate rachis and the conidia is globose in shape
(<3.5 lm diameter). The spore balls representing dense clusters of large numbers of conidiogenous cells and conidia (lactophenol cotton blue stain,
9400).
FIG. 1. Perikeratic hyperaemia with stromal keratitis.
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Mycotic keratitis is an important ophthalmic problem in all
parts of the world; it is a major cause of visual loss especially
in developing countries, where a large part of the population
works in agriculture. Risk factors include the widespread use
of broad-spectrum antibiotics and steroids, the frequent
and sometimes prolonged use of contact lenses, and the
growing number of corneal surgeries. Ocular infections
caused by Beauveria bassiana are extremely rare in humans
and there are few reports in the literature [7,12–14].
Beauveria bassiana is actually a fungus that grows in soils
naturally all over the world. It acts as a parasite on many
different insect species causing white muscardine disease. It is
used in agriculture in pest control as a natural biological
insecticide [15–17].
Identification of Beauveria species by conventional myco-
logical methods is often difficult. Molecular techniques such as
ITS rDNA and LSU rDNA D1–D2 sequencing have become
reliable and are highly suitable tools for rapid identification of
human pathological moulds [18–20].
In this report, the patient with a fungal corneal infection had
agricultural experience. Although phenotypical characteriza-
tion of Beauveria species was controversial and not sufficient to
differentiate among strains [21], a further molecular study
revealed almost 100% identity with sequences deposited in the
GenBank Nucleotide Database, which were able to identify the
species as B. bassiana. In particular the rapid DNA extraction
method allowed a rapid sequencing result.
This isolate displayed in vitro resistance to most antifungal
agents tested, including amphotericin B, which was empirically
used in topical formulation. The in vivo response shows a
stabilization of the corneal lesion, allowing amphotericin B to
inhibit worsening of the disease as seen in previous reports [22].
The underlining disease, Fuchs’ dystrophy, mandated a
surgical option as the only way of clearing the focus of infection
[13]. As lamellar keratoplasty would have been ineffective in
our patient; we chose to perform a penetrating keratoplasty
(PK) with topical use of amphotericin B [7]. Although
susceptibility testing has been standardized for the most
common aetiological agents of invasive fungal disease, like
Aspergillus and conidia-forming moulds, the clinical significance
of this result is not clear and meaningful data are difficult to
generate. This is particularly true for amphotericin B, whose in
vitro MIC values are frequently misleading. The demand for
fungal susceptibility testing, created in part by the increase in
serious fungal infections and the availability of alternative
therapeutic regimens, strongly require more scientific efforts
to correlate MIC results with clinical outcome.
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